Valrubicin

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Valrubicin
Valrubicin.svg
Clinical data
AHFS/Drugs.com Consumer Drug Information
MedlinePlus a611021
Pregnancy
category
  • US: C (Risk not ruled out)
Routes of
administration
Intravesical
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability Negligible
Protein binding >99%
Metabolism Negligible
Excretion In urine
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
ChEMBL
ECHA InfoCard 100.205.793 Edit this at Wikidata
Chemical and physical data
Formula C34H36F3NO13
Molar mass 723.644 g/mol
3D model (JSmol)
  (verify)

Valrubicin (N-trifluoroacetyladriamycin-14-valerate, trade name Valstar) is a chemotherapy drug used to treat bladder cancer. Valrubicin is a semisynthetic analog of the anthracycline doxorubicin, and is administered by infusion directly into the bladder.

It was originally launched as Valstar in the U.S. in 1999 for intravesical therapy of Bacille Calmette-Guérin (BCG)-refractory carcinoma in situ of the urinary bladder in patients in whom cystectomy would be associated with unacceptable morbidity or mortality; however, it was voluntarily withdrawn in 2002 due to manufacturing issues.[1] Valstar was relaunched on September 3, 2009.[2]

Side effects[edit]

References[edit]